Griffin Budde։ New Data Continue to Support Signatera Use in Merkel Cell Carcinoma
Griffin Budde, Director of Oncology Sales – Cutaneous at Natera, shared a post on LinkedIn: “‘Conclusions and Relevance: This study found that ctDNA was more accurate than MCPyV antibody testing […]
Read the full articleYou might also wanna read
Natera's Signatera Wins EU Certification for Cancer Recurrence Monitoring
Certification allows Natera to keep offering the cancer-recurrence test across the EU as the bloc phases out its previous device framework.
Natera, Aveta Biomics to Incorporate MRD Testing into Phase 3 Cancer Trial
The Signatera test will serve as a secondary endpoint in a study of oral immunotherapy in locally advanced head and neck squamous cell carci
Natera MRD Test for Bladder Cancer Nabs Top-Level US Recommendation
The National Comprehensive Cancer Network has given Signatera a Category 1 recommendation in updated clinical practice guidelines.
Natera's Signatera Wins First MRD Approval in Japan for Colorectal Cancer
The PMDA cleared the tumor-informed liquid biopsy test for use in the adjuvant setting; Natera plans to get approval for muscle-invasive bla
Personalized mRNA vaccine shows promise in preventing melanoma recurrence when combined with immunotherapy
A study finds that an mRNA vaccine is highly effective at preventing recurrence of this dangerous skin cancer, when used in combination with
share.google·1mo ago
Senator questions Merck over patent strategy for blockbuster cancer drug Keytruda
In a letter, Sen. Maggie Hassan cited ICIJ's Cancer Calculus investigation and expressed concerns that the pharma giant is boosting profits
Comments
Sign in to join the conversation.
No comments yet. Be the first.